Compass Therapeutics Inc Ordinary Shares CMPX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CMPX is a good fit for your portfolio.
News
-
Compass Therapeutics Gets FDA Fast-Track for Cancer Treatment
-
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
-
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
-
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
-
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
-
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
-
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
-
Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Trading Information
- Previous Close Price
- $1.72
- Day Range
- $1.70–1.74
- 52-Week Range
- $1.16–3.60
- Bid/Ask
- $1.66 / $1.74
- Market Cap
- $239.41 Mil
- Volume/Avg
- 11,504 / 372,700
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 32
Comparables
Valuation
Metric
|
CMPX
|
IGMS
|
MRSN
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.46 | 2.91 | 11.32 |
Price/Sales | — | 247.32 | 10.90 |
Price/Cash Flow | — | — | — |
Price/Earnings
CMPX
IGMS
MRSN
Financial Strength
Metric
|
CMPX
|
IGMS
|
MRSN
|
---|---|---|---|
Quick Ratio | 19.54 | 7.95 | 3.29 |
Current Ratio | 19.73 | 8.18 | 3.36 |
Interest Coverage | — | — | −44.11 |
Quick Ratio
CMPX
IGMS
MRSN
Profitability
Metric
|
CMPX
|
IGMS
|
MRSN
|
---|---|---|---|
Return on Assets (Normalized) | −20.35% | −44.52% | −49.57% |
Return on Equity (Normalized) | −21.81% | −84.37% | −211.52% |
Return on Invested Capital (Normalized) | −26.16% | −77.23% | −146.81% |
Return on Assets
CMPX
IGMS
MRSN
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vpdkwxrbh | Drz | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mjnpyfvhp | Wdyjygq | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vldvvdhp | Dvkhrtr | $103.7 Bil | |
MRNA
| Moderna Inc | Mzkgsfh | Qwb | $47.9 Bil | |
ARGX
| argenx SE ADR | Cjkgqqtbw | Dtzj | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Sykwzrk | Vpzw | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gqyrkwt | Gcbzdhx | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fgbksyllt | Ljxtbgw | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Pycwlgfny | Scdrqh | $12.8 Bil | |
INCY
| Incyte Corp | Hzwptrt | Gcxbmy | $12.1 Bil |